Clinical trial
An Open-Label Extension Study of Patients With Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704
NCT00455195 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Extension Study of Patients With Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 31, 2007
- Completion date
- November 30, 2008
- Enrollment
- 81 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.
acid maltase deficiency (amd), glycogen storage disease type ii (gsd-ii), glycogenesis type ii, pompe disease (late-onset)